NZ331376A - Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening - Google Patents

Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Info

Publication number
NZ331376A
NZ331376A NZ331376A NZ33137697A NZ331376A NZ 331376 A NZ331376 A NZ 331376A NZ 331376 A NZ331376 A NZ 331376A NZ 33137697 A NZ33137697 A NZ 33137697A NZ 331376 A NZ331376 A NZ 331376A
Authority
NZ
New Zealand
Prior art keywords
viral drug
indicator gene
resistance
patient
determining
Prior art date
Application number
NZ331376A
Other languages
English (en)
Inventor
Daniel J Capon
Christos John Petropoulous
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of NZ331376A publication Critical patent/NZ331376A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ331376A 1996-01-29 1997-01-29 Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening NZ331376A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59300996A 1996-01-29 1996-01-29
PCT/US1997/001609 WO1997027319A1 (en) 1996-01-29 1997-01-29 Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Publications (1)

Publication Number Publication Date
NZ331376A true NZ331376A (en) 2000-03-27

Family

ID=24372979

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ331376A NZ331376A (en) 1996-01-29 1997-01-29 Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Country Status (18)

Country Link
EP (2) EP1170380B1 (2)
JP (1) JP4183749B2 (2)
KR (1) KR100537153B1 (2)
CN (1) CN1263867C (2)
AP (1) AP9801360A0 (2)
AT (1) ATE447621T1 (2)
AU (1) AU732255B2 (2)
CA (1) CA2216126C (2)
DE (2) DE69739645D1 (2)
EA (1) EA005426B1 (2)
ES (1) ES2175355T3 (2)
HU (1) HUP9900388A3 (2)
IL (1) IL125464A (2)
NO (1) NO983421L (2)
NZ (1) NZ331376A (2)
PL (1) PL328068A1 (2)
RO (1) RO118887B1 (2)
WO (1) WO1997027319A1 (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218541T1 (de) 1992-08-25 2002-06-15 Searle & Co Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
US6221578B1 (en) 1996-01-26 2001-04-24 Virco N.V. Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AU8897698A (en) * 1997-07-30 1999-02-22 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
WO1999051776A1 (en) * 1998-04-07 1999-10-14 Southern Research Institute High-throughput method for screening for antiviral activity
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
CN1532290A (zh) * 1998-05-26 2004-09-29 病毒科学公司 监控非核苷类逆转录酶抑制剂抗逆转录病毒治疗的途径与方法
US20030148307A1 (en) 1998-06-19 2003-08-07 Department Of Health & Human Services, C/O Centers Of Disease Control And Prevention Method and kit for detecting resistance to antiviral drugs
DE69924118T2 (de) * 1998-06-19 2005-12-22 The Government of the United States of America, as represented by the Secretary Centers for Disease and Prevention, Office of Technology Verfahren und reagentiensatz zur erkennung von antiviralen wirkstoff resistenzen
US6787126B1 (en) 1998-06-19 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Method and kit for detecting resistance to antiviral drugs
BR9912209A (pt) * 1998-06-24 2002-11-05 Virologic Inc Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids
MXPA01012270A (es) 1999-05-28 2003-06-24 Virco Nv Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos.
EP1326640A4 (en) * 2000-09-15 2004-12-15 Virologic Inc NON-NUCLEOSIDIC REVERSE-TRANSCRIPTASE INHIBITOR AS ANTIRETROVIRAL THERAPY
WO2002033402A2 (en) * 2000-10-20 2002-04-25 Virco Bvba Establishment of biological cut-off values for predicting resistance to therapy
EP1356082A2 (en) 2000-10-20 2003-10-29 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7247439B1 (en) 2001-06-04 2007-07-24 Monogram Biosciences, Inc. Method of evaluating a patient antibody response to envelope proteins of a virus
US7097970B2 (en) 2001-06-04 2006-08-29 Monogram Biosciences, Inc. Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs
WO2003040390A2 (en) 2001-11-08 2003-05-15 Tibotec Pharmaceuticals Ltd. Protease assay for therapeutic drug monitoring
US7217506B2 (en) 2002-07-01 2007-05-15 Tibotec Pharmaceuticals, Ltd. Mutational profiles in HIV-1 protease correlated with phenotypic protease inhibitor resistance
AU2003251732B2 (en) 2002-07-01 2008-09-18 Tibotec Pharmaceuticals Ltd. New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
DE20218008U1 (de) 2002-11-21 2003-03-06 FESTO AG & Co., 73734 Esslingen Anordnung von mehreren Handhabungsvorrichtungen
US8603736B2 (en) 2004-06-07 2013-12-10 Monogram Biosciences, Inc. Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
US8178291B2 (en) 2005-02-18 2012-05-15 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
CA2601922C (en) 2005-02-18 2020-11-24 Monogram Biosciences, Inc. Methods and compositions for determining anti-hiv drug susceptibility and replication capacity of hiv
EP2458018A3 (en) 2005-05-27 2012-07-25 Monogram BioSciences, Inc. Methods and compositions for determining resistance of HIV-1 to protease inhibitors
WO2006133267A2 (en) 2005-06-06 2006-12-14 Monogram Biosciences, Inc. Methods and compositions for determining altered susceptibility of hiv-1 to anti-hiv drugs
US9506121B2 (en) 2005-06-06 2016-11-29 Monogram Biosciences, Inc. Methods for determining resistance or susceptibility to HIV entry inhibitors
WO2007146336A2 (en) 2006-06-13 2007-12-21 Monogram Biosciences, Inc. Molecular determinants associated with enhanced ability to enter cells expressing cxcr4
US8338101B2 (en) * 2007-01-23 2012-12-25 Virco Bvba Method for designing a drug regime for HIV-infected patients
WO2008106115A2 (en) 2007-02-26 2008-09-04 Monogram Biosciences, Inc. Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
US20190183855A1 (en) * 2016-08-10 2019-06-20 Riken Composition for treating hepatitis b, and method for evaluating replication activity of hepatitis b virus
RU2646472C1 (ru) * 2016-10-07 2018-03-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ оценки эффективности терапии инфекции вызванной вирусом герпеса человека 6 типа у детей
US10793876B2 (en) * 2016-12-29 2020-10-06 Virongy L.L.C. Retro- and lenti-HBV hybrid vectors and constructs
CN109722465B (zh) * 2019-01-07 2022-02-01 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) 一种hiv耐药检测载体和构建方法
JP7773731B2 (ja) * 2020-06-24 2025-11-20 シァメン・ユニヴァーシティ 薬物スクリーニングモデル及びＨＢＶ ｃｃｃＤＮＡを標的化する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291893A1 (en) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
ATE118247T1 (de) * 1988-09-27 1995-02-15 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält.
HU209835B (en) * 1988-12-07 1994-11-28 Univ Osaka Res Found Method for producing of retrovirus protease, reverse transcriptase and integrase
EP0414475B1 (en) * 1989-08-25 1997-12-10 Chiron Corporation Methods for culturing HCV in B- or T-lymphocyte cell lines
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
WO1995022622A1 (en) * 1994-02-18 1995-08-24 University Of Washington Methods and compositions for screening for anti-aids drugs
US5733543A (en) * 1994-04-29 1998-03-31 Nabel; Gary J. Introduction of HIV-protective genes into cells by particle-mediated gene transfer
WO1995030763A2 (en) * 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AU8897698A (en) * 1997-07-30 1999-02-22 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Also Published As

Publication number Publication date
CN1263867C (zh) 2006-07-12
CN1213407A (zh) 1999-04-07
IL125464A0 (en) 1999-03-12
AU732255B2 (en) 2001-04-12
ATE447621T1 (de) 2009-11-15
CA2216126C (en) 2009-03-31
EA005426B1 (ru) 2005-02-24
EP0852626A4 (en) 1999-08-25
ES2175355T3 (es) 2002-11-16
DE69711584T2 (de) 2002-11-07
EP1170380A3 (en) 2003-05-02
NO983421L (no) 1998-09-25
HUP9900388A3 (en) 2005-03-29
KR100537153B1 (ko) 2006-12-15
EP0852626B1 (en) 2002-04-03
IL125464A (en) 2007-12-03
EP1170380A2 (en) 2002-01-09
KR19990082129A (ko) 1999-11-15
AU1952897A (en) 1997-08-20
JP4183749B2 (ja) 2008-11-19
CA2216126A1 (en) 1997-07-31
AP9801360A0 (en) 1998-12-31
EA199800669A1 (ru) 1999-02-25
EP0852626A1 (en) 1998-07-15
WO1997027319A1 (en) 1997-07-31
JP2000503849A (ja) 2000-04-04
NO983421D0 (no) 1998-07-24
DE69739645D1 (de) 2009-12-17
EP1170380B1 (en) 2009-11-04
DE69711584D1 (de) 2002-05-08
RO118887B1 (ro) 2003-12-30
PL328068A1 (en) 1999-01-04
HUP9900388A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
NZ331376A (en) Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
Wanagat et al. Mitochondrial DNA deletion mutations colocalize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia
EP2142661B1 (en) Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
ES2170220T3 (es) Procedimiento para detectar sustancias biologicamente activas.
ATE408829T1 (de) Verfahren und assaykits zum nachweis mononuklearer zellphänotypen
AU4050597A (en) Apparatus and method for real-time measurement of cellular response
EP1965213A3 (en) Microarrays and uses therefor
AU7703998A (en) Methods for detection of nucleic acid sequences in urine
DK1513878T3 (da) Sammensætninger og fremgangsmåder til analyse af Apo B48 og Apo B100
Smart et al. Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro
WO1997030179B1 (en) Determining exposure to ionizing radiation agent with persistent biological markers
Conroy et al. A rapid and sensitive fluorescence assay for angiotensin-converting enzyme
DE60229593D1 (de) Verfahren zur Quantifizierung von Nukleinsäuren mittels Bestimmung der Zellzahl
US4975365A (en) Assay for measuring DNA cell repair potential
CA2229558C (en) Mono-allelic mutation analysis for identifying germline mutations
Yamada et al. Lymphocyte metallothionein-mRNA as a sensitive biomarker of cadmium exposure
EP1136568A4 (en) METHOD FOR DETERMINING NUCLEIC ACID
DK1416278T3 (da) Fremgangsmåder til forbedret diagnosticering af dysplasier
PT912901E (pt) Metedo e reagentes para monitorizacao dos niveis sanguineos de compostos antiagregantes plaquetares
Beeser et al. A German prothrombin time proficiency testing program
EP0348212A3 (en) Method for determining susceptibility of an organism to a potentially toxic agent
ATE317454T1 (de) Verfahren zur aktivitätsbestimmung einer substanz mittels eines funktionellen in vitro tests
JP2024082849A (ja) 被験物質のげっ歯類小核誘発の有無を予測する方法
SU974271A1 (ru) Способ определени степени дезинтеграции клеток
CA2198731A1 (en) Assay and reagent kit for the quantitative in vitro determination in biological specimens of the activity of proteins causing multi-drug resistance in tumors

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired